Advertisement

The Heart in Diabetes: Results of Trials

  • Giulio Zuanetti
  • Roberto Latini
  • Aldo P. Maggioni

Abstract

It has been known for many years that diabetes has profound consequences on the cardiovascular system leading to increased morbidity and mortality in diabetic patients [1]. In the last years, the completion of several large trials allowed to gather critical information on the efficacy and safety of different drugs in patients with a variety of cardiovascular diseases. In most of these trials diabetic patients, generally identified on the basis of clinical history and with no distinction between type 1 and type 2 diabetes, represented an important proportion of the randomized population, ranging between 10 and 25 % in most cases. In this brief review, we will summarize how these trials helped in widening our knowledge of the pathophysiology, prognosis and pharmacological treatment of diabetic patients with cardiovascular disease. Table 6–1 shows the meaning of the acronyms of the trials quoted in this review, where three specific settings will be discussed: acute myocardial infarction (MI); congestive heart failure (CHF) and treatment of myocardial ischemia with coronary angioplasty (PTCA).

Keywords

Diabetic Patient Acute Myocardial Infarction Congestive Heart Failure Patient Scandinavian Simvastatin Survival Study Concomitant Risk Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jacoby RM, Nesto RW. Acute myocardial infarction in the diabetic patient: pathophysiology, clinical course and prognosis. J Am Coll Cardiol 1992; 20:736–44.PubMedCrossRefGoogle Scholar
  2. 2.
    Smith JW, Marcus FI, Serokman R, Multicenter Postinfarction Research Group. Prognosis of patients with diabetes mellitus after acute myocardial infarction. Am J Cardiol 1984; 54:718–21.PubMedCrossRefGoogle Scholar
  3. 3.
    Stone PH, Muller JE, Hartwell T, et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. J Am Coll Cardiol 1989; 14:49–57.PubMedCrossRefGoogle Scholar
  4. 4.
    Zuanetti G, Latini R, Maggioni AP, Santoro L, Franzosi MG, GISSI-2 Investigators. Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study. J Am Coll Cardiol 1993; 22:1788–94.PubMedCrossRefGoogle Scholar
  5. 5.
    Lee KL, Woodlief LH, Topol EJ, Weaver D, Betriu A, Col J, Simoons M, Aylward P, Van de Werf F, Califf RM, for the GUSTO-1 Investigators. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41 021 patients. Circulation 1995;91:1659–68.PubMedCrossRefGoogle Scholar
  6. 6.
    Mueller HS, Cohen LS, Braunwald E, Forman S, Feit F, Ross A, Schweiger M, Cabin H, Davison R, Miller D, Solomon R, Knatternd GL, for the TIMI Investigators. Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction. Analyses of patient subgroups in the thrombolysis in myocardial infarction (TIMI) trial, phase 11. Circulation 1992; 85:1254–64.PubMedCrossRefGoogle Scholar
  7. 7.
    Malmberg K, Rydén L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, Wedel H, Welin L, on behalf of the DIG AMI Study Group. Randomized trial of insulin glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI Study): effects on mortality at 1 year. J Am Coll Cardiol 1995; 26:57–65.PubMedCrossRefGoogle Scholar
  8. 8.
    Malmberg K for the DIG AMI (Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ 1997; 314:1512–5.PubMedCrossRefGoogle Scholar
  9. 9.
    Aoki I, Shimoyama K, Aoki N, Homori M, Yanagisawa A, Nakahara K, Kawai Y, Kitamura S, Lshikawa K. Platelet-dependent thrombin generation in patients with diabetes mellitus: effects of glycemic control on coagulability in diabetes. J Am Coll Cardiol 1996; 27:560–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343:311–22.Google Scholar
  11. 11.
    Granger CB, Califf RM, Young S, Candela R, Samaha J, Worley S, Kereiakes DJ, Topol EJ, and the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. J Am Coll Cardiol 1993; 21:920–5.PubMedCrossRefGoogle Scholar
  12. 12.
    ISIS-2 Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17187 cases of suspected acute myocardial infarction: ISIS 2 Lancet 1988; ii:349–60.Google Scholar
  13. 13.
    Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308:81–106.CrossRefGoogle Scholar
  14. 14.
    Kendall MJ, Lynch KP, Hjaimarson A, Kjekshus J. B-Blockers’ and sudden cardiac death. Ann Intern Med 1995; 123:358–67.PubMedCrossRefGoogle Scholar
  15. 15.
    Malmberg K, Ryden L. Intense metabolic control decreases long-term mortality in diabetics with acute myocardial infarction: predictors of one year mortality. J Am Coll Cardiol 1996; 27 Suppl. A,82A.CrossRefGoogle Scholar
  16. 16.
    Gruppo Italiano per lo Studio della Soprawivenza nell’infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343:1115–22.Google Scholar
  17. 17.
    Zuanetti G, Latini R, Maggioni AP, Franzosi MG, Santoro L, Tognoni G, on behalf of GISSI-3 Investigators. Effect of the ACE-inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: the data from the GISSI-3 study. Circulation 1997; 96:4239–45.PubMedCrossRefGoogle Scholar
  18. 18.
    Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Oisson AG, Thorgeirsson G, The Scandinavian Simvastatin Survival Study (4S) Group. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20:614–20.PubMedCrossRefGoogle Scholar
  19. 19.
    Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Packer M, Bristow MR, Cohn JN. The effect of Carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1987; 316:1429–35.CrossRefGoogle Scholar
  21. 21.
    The CONSENSUS Trial Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316:1429–35.CrossRefGoogle Scholar
  22. 22.
    The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293–302.CrossRefGoogle Scholar
  23. 23.
    The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327:685–91.CrossRefGoogle Scholar
  24. 24.
    Shindier DM, Kostis JB, Yusuf S, Quinones MA, Pitt B, Stewart D, Pinkett T, Ghali JK, Wilson AC, for the SOLVD Investigators. Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trials and registry. Am J Cardiol 1996; 77:1017–20.CrossRefGoogle Scholar
  25. 25.
    Moyé LA, Pfeffer MA, Wun CC, Davis BR, Geltman E, Hayes D, Farnham DJ, Randall OS Dinh H, Arnold JMO, Kupersmith J, Hager D, Glasser SP, Biddle T, Hawkins CM, Braunwald E, for the SAVE Investigators. Uniformity of Captopril benefit in the SAVE study: subgroup analysis. Eur Heart J1994; 15:2–8PubMedCrossRefGoogle Scholar
  26. 26.
    The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342:821–28.Google Scholar
  27. 27.
    Torp-Pedersen C, Kober L, Carisen J, on behalf of the TRACE Study Group. Angiotensinconverting enzyme inhibition after myocardial infarction: the Trandolapril Cardiac Evaluation Study. Am Heart J 1996; 132:235–43.PubMedCrossRefGoogle Scholar
  28. 28.
    Waagstein F, Hjaimarson A, Varnauskas E, Wallentin J. Effect of chronic betaadrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975; 37:1022–36.PubMedCrossRefGoogle Scholar
  29. 29.
    Kjeskhus J, Gilpin E, Cali G, Blackey AR, Henning H, Ross J Jr. Diabetic patients and betablockers after acute myocardial infarction. Eur Heart J 1990; 11:43–50.Google Scholar
  30. 30.
    Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger R, Kybo SH, Narahara KA, Robertson AD, Krueger S, for the MOCHA Investigators. Effect of Carvedilol on left ventricular function and mortality in diabetic versus non-diabetic patients with ischaemic or non-ischaemic dilated cardiomyopathy. Eur Heart J 1996; 17(Suppl.):78.Google Scholar
  31. 31.
    Aronson D, Bloomgarden Z, Rayfield EJ. Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol 1996; 27:528–35.PubMedCrossRefGoogle Scholar
  32. 32.
    The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996;335:217–25.CrossRefGoogle Scholar
  33. 33.
    Topol EJ, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin 63 blockade with percutaneous coronary intervention. JAMA 1997; 278:479–84.PubMedCrossRefGoogle Scholar
  34. 34.
    The HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: The design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can J Cardiol 1996; 12:127–37.Google Scholar
  35. 35.
    Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338:645–52.PubMedCrossRefGoogle Scholar
  36. 36.
    Pahor M, Psaty BM, Furberg C. Treatment of hypertensive patients with diabetes. Lancet 1998; 351:689–690.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1998

Authors and Affiliations

  • Giulio Zuanetti
    • 1
  • Roberto Latini
    • 1
  • Aldo P. Maggioni
    • 2
  1. 1.Istituto Mario NegriMilanoItaly
  2. 2.Centro Studi ANMCOFirenzeItaly

Personalised recommendations